Berdyshev Evgeny V, Gorshkova Irina, Skobeleva Anastasia, Bittman Robert, Lu Xuequan, Dudek Steven M, Mirzapoiazova Tamara, Garcia Joe G N, Natarajan Viswanathan
Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA.
J Biol Chem. 2009 Feb 27;284(9):5467-77. doi: 10.1074/jbc.M805186200. Epub 2009 Jan 1.
Novel immunomodulatory molecule FTY720 is a synthetic analog of myriocin, but unlike myriocin FTY720 does not inhibit serine palmitoyltransferase. Although many of the effects of FTY720 are ascribed to its phosphorylation and subsequent sphingosine 1-phosphate (S1P)-like action through S1P(1,3-5) receptors, studies on modulation of intracellular balance of signaling sphingolipids by FTY720 are limited. In this study, we used stable isotope pulse labeling of human pulmonary artery endothelial cells with l-[U-(13)C, (15)N]serine as well as in vitro enzymatic assays and liquid chromatography-tandem mass spectrometry methodology to characterize FTY720 interference with sphingolipid de novo biosynthesis. In human pulmonary artery endothelial cells, FTY720 inhibited ceramide synthases, resulting in decreased cellular levels of dihydroceramides, ceramides, sphingosine, and S1P but increased levels of dihydrosphingosine and dihydrosphingosine 1-phosphate (DHS1P). The FTY720-induced modulation of sphingolipid de novo biosynthesis was similar to that of fumonisin B1, a classical inhibitor of ceramide synthases, but differed in the efficiency to inhibit biosynthesis of short-chain versus long-chain ceramides. In vitro kinetic studies revealed that FTY720 is a competitive inhibitor of ceramide synthase 2 toward dihydrosphingosine with an apparent K(i) of 2.15 microm. FTY720-induced up-regulation of DHS1P level was mediated by sphingosine kinase (SphK) 1, but not SphK2, as confirmed by experiments using SphK1/2 silencing with small interfering RNA. Our data demonstrate for the first time the ability of FTY720 to inhibit ceramide synthases and modulate the intracellular balance of signaling sphingolipids. These findings open a novel direction for therapeutic applications of FTY720 that focuses on inhibition of ceramide biosynthesis, ceramide-dependent signaling, and the up-regulation of DHS1P generation in cells.
新型免疫调节分子FTY720是麦角硫因的合成类似物,但与麦角硫因不同的是,FTY720不抑制丝氨酸棕榈酰转移酶。尽管FTY720的许多作用归因于其磷酸化以及随后通过S1P(1,3 - 5)受体产生的类似1 - 磷酸鞘氨醇(S1P)的作用,但关于FTY720对信号鞘脂细胞内平衡调节的研究有限。在本研究中,我们使用l - [U - (13)C, (15)N]丝氨酸对人肺动脉内皮细胞进行稳定同位素脉冲标记,以及体外酶促测定和液相色谱 - 串联质谱方法,以表征FTY720对鞘脂从头生物合成的干扰。在人肺动脉内皮细胞中,FTY720抑制神经酰胺合酶,导致二氢神经酰胺、神经酰胺、鞘氨醇和S1P的细胞水平降低,但二氢鞘氨醇和二氢鞘氨醇1 - 磷酸(DHS1P)水平升高。FTY720诱导的鞘脂从头生物合成调节与伏马菌素B1(一种经典的神经酰胺合酶抑制剂)相似,但在抑制短链与长链神经酰胺生物合成的效率上有所不同。体外动力学研究表明,FTY720是神经酰胺合酶2对二氢鞘氨醇的竞争性抑制剂,表观K(i)为2.15微摩尔。通过使用小干扰RNA沉默SphK1/2的实验证实,FTY720诱导的DHS1P水平上调由鞘氨醇激酶(SphK)1介导,而非SphK2。我们的数据首次证明了FTY720抑制神经酰胺合酶并调节信号鞘脂细胞内平衡的能力。这些发现为FTY720的治疗应用开辟了一个新方向,该方向聚焦于抑制神经酰胺生物合成、神经酰胺依赖性信号传导以及细胞中DHS1P生成的上调。